Antigen-presenting complex-binding compositions and uses...

Details Antigen-presenting complex-binding compositions and uses... Antigen-presenting complex-binding compositions and uses...

2004-03-25

2009-12-29

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S134100, C424S178100, C424S183100, C530S387100, C530S387300

Reexamination Certificate

active

07638124

ABSTRACT:
A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed.

REFERENCES:
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3839153 (1974-10-01), Schuurs et al.
patent: 3850578 (1974-11-01), McConnell
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3853987 (1974-12-01), Dreyer
patent: 3867517 (1975-02-01), Ling
patent: 3879262 (1975-04-01), Schuurs et al.
patent: 3901654 (1975-08-01), Gross
patent: 5591829 (1997-01-01), Matsushita
patent: 5695928 (1997-12-01), Stewart et al.
patent: 5952471 (1999-09-01), Griffiths Lawson
patent: 6054297 (2000-04-01), Carter et al.
patent: 6291160 (2001-09-01), Lerner et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6416738 (2002-07-01), Theodore et al.
patent: 6992176 (2006-01-01), Reiter et al.
patent: 2003/0129191 (2003-07-01), Theodore et al.
patent: 2003/0165993 (2003-09-01), Buechler et al.
patent: 2003/0223994 (2003-12-01), Hoogenboom et al.
patent: 2005/0152912 (2005-07-01), Reiter et al.
patent: 2005/0250833 (2005-11-01), Attali et al.
patent: 2005/0255101 (2005-11-01), Reiter et al.
patent: 2005/0287141 (2005-12-01), Reiter
patent: 2007/0196369 (2007-08-01), Hoogenboom et al.
patent: 1178116 (2002-02-01), None
patent: WO 91/12332 (1991-08-01), None
patent: WO 95/29193 (1995-11-01), None
patent: WO 97/02342 (1997-01-01), None
patent: WO 99/49893 (1999-10-01), None
patent: WO 01/96401 (2001-12-01), None
patent: WO 03/068201 (2003-08-01), None
patent: WO 03/070752 (2003-08-01), None
patent: WO 2004/084798 (2004-07-01), None
patent: WO 2006/103429 (2006-10-01), None
Daugherty et al., Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a muring monoclonal antibody directed against . . . , Nucleic Acids Research, vol. 19 No. 9, pp. 2471-2476 (May 1991).
GenPept ABG38407 “immunoglobulin light chain variable region [Homo sapiens],” Jul. 2006.
GenPept AAO45455 “immunoglobulin kappa chain variable region [Homo sapiens],” Nov. 2003.
Poljak et al., Structure and specificity of antibody molecules, Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences, vol. 272, pp. 43-51 (Nov. 1975).
Shiono et al., “Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells fromMyasthenia gravispatients suggests autoimmunization in the tumor,” International Immunology, vol. 15 No. 8, pp. 903-913 (Aug. 2003).
Shriner et al., “Comparison of the human immune response to conjugate and polysaccharide pneumococcal vaccination using a reconstituted SCID mouse model,” Vaccine, vol. 24 No. 49-50, pp. 7197-7203 (Nov. 2006).
Reiter et al. “Peptide-Specific Killing of Antigen-Presenting Cells by A Recombinant Antibody-Toxin Fusion Protein Targeted to Major Histocompatibility Complex/Peptide Class I Complexes With T Cell Receptor-Like Specifity”, Proc. Natl. Acad. Sci. USA, 94(9): 4631-4636, 1997.
Andersen et al. “A Recombinant Antibody With the Antigen-Specific, Major Histocompatibility Complex-Restricted Specifity of T Cells”, Proceedings of the National Academy of Sciences, 93(5): 1820-1824, 1996.
Rudikoff et al. “Single Amino Acid Substitution Altering Antigen-Binding Specifity”, Proceedings of the National Academy of Sciences, USA, 79(6): 1979-1983, 1982.
Stedman Definition “Fab Fragment”, Stedman's Online Medical Dictionary, 27th Edition. www.stedmans.com.
??? Definition “Fab”, The Online Medical Ddictionary, cancerweb.ncl.ac.uk/omd/.
Engberg et al. “Recombinent Antibodies With the Antigen-Specific, MHC Restricted Specifity of T Cells: Novel Reagents for Basic and Clinical Investigations and Immunotherpy”, Immunotechnology, 4(Nos. 3-4): 273-278, 1999.
Saito et al. “In Vivo Selection of T-Cell Receptor Junctional Region Sequences by HLA-A2 Human T-Cell Lymphotropic Virus Type 1 Tax11-19 Peptide Complexes”, Journal of Virology, 75(2): 1065-1071, 2001.
Polakova et al. “Antibodies Directed Against the MHC-I Molecule H-2Dd Complexed With An Antigenic Peptide: Similarities to A T Cell Receptor With the Same Specifity”, The Journal of Immunology, 165: 5703-5712, 2000.
Chung et al. “Competitive Inhibition In Vivo and Skewing of the T Cell Repertoire of Antigen-Specific CTL Priming by an Anti-Peptide-MHC Monoclonal Antbody”, The Journal of Immunology, 167: 699-707, 2001.
Robert et al. “Antibody-Conjugated MHC Class I Tetramers Can Target Tumor Cells For Specific Iysis by T Lumphocytes”, European Journal of Immunology, 30: 3165-3170, 2000.
Yoshida et al. “Isolation And Characterization Of Retrovirus From Cell Lines Of Human Adult T-Cell Leukemia And Its Implication In the Disease”, PNAS, 79:2031-2035, 1982.
Köhler et al. “Continuous Cultures Of Fused Cells Secreting Antibody Of Predefined Specificity”, Nature, 256:495-497, 1975.
Harding et al. “Quantitation Of Antigen-Presenting Cell MHC Class II/ Peptide Complexes Necessary For T-Cell Stimulation”, Nature, 346: 574-576, 1990.
Christinck et al. “Peptide Binding To Class I MHC On Living Cels And Quantitation of Compplexes Required For CTL Lysis”, Nature, 352: 67-70, 1991.
Aharoni et al. “Immunomodulation Of Experimental Allergic Encephalomyelitis By Antibodies To The Antigen-Ia Complex”, Nature, 351: 147-149, 1991.
Haard et al. “A Large Non-Immunized Human Fab Fragment Phage Library That Permits Rabipd Isolation And Kinetic Analysis Of High Affinity Antibodies”, The Journal of Biological Chemistry, 274(26): 18218-18230, 1999.
Winter et al. “Man-Made Antibodies”, Nature, 349: 293-299, 1991.
Stubbs et al. “Influence Of Core Fucosylation On TheFlexibility Of A Biantennary N-Linked Oligosaccharide”, Bichemistry, 35: 937-947, 1996.
Hoogenboom et al. “By-Passing Immunisation—Human Antibodies From Synthetic Repertoires Of Germline VH Gene Segments Rearranged In Vitro”, Journal of Molecular Biology, 227: 381-388, 1992.
Grassmann et al. “Transformation To Continuous Growth Of Primary Human T Lymphocytes By Human T-Cell Leukemia Virus Type I X-Region Genes Tranduced By A Herpesvirus Saimiri Vector”, PNAS, 86: 3351-3355, 1989.
Poiesz et al. “Detection And Isolation Of Type C Retrovirus Particles From Fresh And Cultured Lymphocytes Of A Patient With Cutaneous T-Cell Lymphoma”, PNAS, 77(12): 7415-7419, 1980.
Porter “The Hydrolysis Of Rabbit γ-Globulin And Antibidies With Crystalline Papain”, Biochemical Journal, 73: 119-126, 1959.
Pozzatti et al. “The Human T-Lymphotropic Virus Type I “Tax” Gene Can Cooperate With The “Ras” Oncogene To Induce Neoplastic Transformation Of Cells”, Molecular and Cellular Biology, 10(1): 413-417, 1990.
Neuberger “Generating High-Avidity Human Mabs InMice”, Nature Biotechnology, 14, 1996.
Bird et al. “Single-Chain Antigen-Binding Proteins”, Science, 242: 423-426, 1988.
Marks et al. “By-Passing Immunization—Human Antibodies From V-Gene Libraries Displayed On Phage”, Journal ofMelcular Biology, 222: 581-597, 1991.
Cote et al. “Generation Of Human Monoclonal Antibodies Reactive With Cellular Antigens”, PNAS, 80: 2026-2030, 1983.
Murphy et al. “A Novel MHC Class II Epitope Expressed In Thymic Medulla But Not Cortex”, Nature, 338:765-768, 1989.
Riechmann et al. “Reshaping Human Antibodies For Therapy”, Nature 332: 323-327, 1988.
Bieganowska et al. “Direct Analysis Of Viral-Specific CD8 T Cells With Soluble HLA-A2/Tax11-19 Tetramer Complexes in Patients With Human T-Cell Lymphotropic Virus-Associated Myelopathy”, he Journal of Immunology, 162:1765-1771, 1999.
Anton et al.

Affiliated with

Also associated with

Rating

Antigen-presenting complex-binding compositions and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antigen-presenting complex-binding compositions and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen-presenting complex-binding compositions and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4145760